
About Remedy Plan
Remedy Plan is a Healthcare company based in Washington (United States) founded in 2011. Metastatic cancer properties are targeted by Remedy Plans containment therapy. It operates on a HealthTech model. Remedy Plan has raised $24.7 million across 3 funding rounds from investors including ARE and Schooner Capital. Remedy Plan offers products and services including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug. Its focus areas include Biotechnology, Oncology, Autoimmune Disorders and Metabolic Disorders. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.
- Headquarters Washington, United States
- SectorsHealthcare
- Website remedyplan.com
- Social LinkedIn X Facebook
- Total Equity Funding$24.7M (USD)
in 3 rounds
- Latest Funding Round$18M (USD), Series B
May 2025
- InvestorsARE
& 1 more
Products & Services of Remedy Plan
Remedy Plan offers a comprehensive portfolio of products and services, including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.
A novel NAMPT inhibitor for oncology treatment is developed.
A NAMPT inhibitor for autoimmune diseases is being researched.
A NAMPT inhibitor for obesity treatment is under development.
Funding Insights of Remedy Plan
Remedy Plan has successfully raised a total of $24.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.7M
- Total Rounds 3
- Last Round Series B β $18M
- First Round $1.5M
(Nov 2018)
- Investors Count 2
All 3 funding rounds of Remedy Plan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $18M | Series B | β | β | |
| Dec 2019 | $5.2M | Series A | β | β | β |
| Nov 2018 | $1.5M | Series A | β | β | β |
2 investors in total: 2 institutional.
Investors in Remedy Plan
Remedy Plan has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE and Schooner Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed across multiple sectors. | schoonercapital.com | Boston, United States | ||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Remedy Plan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Remedy Plan
18 people are tracked at Remedy Plan (5 in leadership, 8 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Greg Crimmins | CEO & Founder | Leadership |
Dennise A. De Jesús-Díaz | Chief Operations Officer | Leadership |
Michael Schelle | Chief Scientific Officer | Leadership |
Marc Rudoltz | Acting Chief Medical Officer | Leadership |
Banumathi Cole | Director, Biology | Leadership |
Frank McCormick | Advisor | Board & advisors |
Ronald Parchem | Advisor | Board & advisors |
Vahe Bedian | Advisor | Board & advisors |
Daniel Portnoy | Advisor | Board & advisors |
Tom Dubensky | Advisor | Board & advisors |
Erika Pearce | Advisor | Board & advisors |
Ed Pearce | Advisor | Board & advisors |
Steve Abella | Advisor | Board & advisors |
Parisa Moghaddam-Taaheri | Program Manager | Team |
Claudia Fabiola Ramos | Research Assistant | Team |
James Digel | Research Technician I | Team |
Min Wu | Senior Scientist, Biology | Team |
Caroline Robb | Senior Project Manager | Team |
Complete people profiles for Remedy Plan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Remedy Plan
3 dated milestones of Remedy Plan across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Remedy Plan is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series B, of $18.0M.
Competitors of Remedy Plan
Remedy Plan has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Remedy Plan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Remedy Plan
The website of Remedy Plan (remedyplan.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 28.4% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Remedy Plan (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Remedy Plan
Complete news archive for Remedy Plan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remedy Plan
Remedy Plan was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Remedy Plan is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Remedy Plan is a funded company, having raised a total of $24.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Nov 2018.
Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.
Remedy Plan offers RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.
Remedy Plan has 2 investors. Key investors include ARE, and Schooner Capital.
